Pharmacogenomics (PGx) Proton Pump Inhibitors CYP2C19 Test
A targeted pharmacogenomic test evaluating CYP2C19 metabolizer status to optimize proton pump inhibitor prescription and dosing, powered by the Helix Exome+® platform.
Turnaround
6-9 days
Requery (SOQO)
≤ 5 minutes
Genes Tested
1
Panel Description
Proton pump inhibitors are prescribed to patients with gastroesophageal reflux disease (GERD), peptic ulcer disease and other conditions related to dysfunctional gastric acid secretion. Certain CYP2C19 metabolizer types may reduce efficacy of PPIs, while others may lead to increased risk for adverse events.
Order This Test
Contact our clinical team to order this panel or learn more.
Indications for Testing
Patients for whom omeprazole, lansoprazole, pantoprazole, and dexlansoprazole are being considered, have been ineffective or caused side effects.
Methodology
This test utilizes next-generation sequencing to determine star alleles and metabolizer status for CYP2C19 and is used to determine drug considerations for omeprazole, lansoprazole, pantoprazole, and dexlansoprazole.
Technical Specifications
Reportable range
CYP2C19: *1-*19, *22-*26, *28-*39
Results based on
Dexlansoprazole, CYP2C19 (PGKB 1A); Lansoprazole, CYP2C19 (PGKB 1A; CPIC A); Omeprazole, CYP2C19 (PGKB 1A; CPIC A); Pantoprazole, CYP2C19 (FDA Section 1; CPIC A).
Genes Tested
1 genes included in this panel
Ordering Information
Turnaround Time
Typically 6-9 days (standard), Typically ≤ 5 minutes (requery)
Preferred Specimen
BD Vacutainer Whole Blood K2 EDTA Collection Tube 4mL or Oragene Dx Saliva Collection Kit
Shipping Instructions
Specimens to arrive at Helix within 96 hours of collection at ambient temperature.
Clinical Description
Proton pump inhibitors are prescribed to patients with gastroesophageal reflux disease (GERD), peptic ulcer disease and other conditions related to dysfunctional gastric acid secretion. Certain CYP2C19 metabolizer types may reduce efficacy of PPIs, while others may lead to increased risk for adverse events.
Patients for whom omeprazole, lansoprazole, pantoprazole, and dexlansoprazole are being considered, have been ineffective or caused side effects.
Ready to order this test?
Contact our clinical team to order the Pharmacogenomics (PGx) Proton Pump Inhibitors CYP2C19 Test for your patients.